Z-Medica, LLC, a leading developer and marketer of hemostatic devices, announces that QuikClot Control+ has been cleared for use by the FDA under the de novo classification process and is designated as a Class II medical device.
QuikClot Control+ is the first and only non-absorbable hemostatic dressing cleared for internal organ space use in severely bleeding patients. QuikClot Control+ is indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding. It may also be used for control of severely bleeding wounds such as surgical wounds and traumatic injuries.
Uncontrolled bleeding is a major cause of preventable deaths and various studies have shown that bleeding-related complications or transfusions due to significant blood loss lead to increased risk of infection, longer ICU stay, longer hospital stay, higher total hospital costs, and increased postoperative morbidity and mortality. Safe and intuitive devices like QuikClot Control+ that improve hemorrhage control can potentially save lives and reduce healthcare costs.
“In a preclinical study, we saw significantly less blood loss after packing with QuikClot Control+ compared to packing with laparotomy sponges,” says Dr. Joshua P. Hazelton, Director of Trauma Research at Cooper University Hospital, who was the principal investigator in the study. “The development of a non-absorbable hemostatic dressing that can be used internally during surgery only enhances our ability to stabilize a severely injured patient. Control+ will become a necessary piece of equipment in our trauma bays and operating rooms.”
Domestically, Z-Medica has already obtained several patents for QuikClot Control+ and has numerous patents granted and pending internationally. QuikClot Control+ will be manufactured in the United States.